Development, Testing, Parameterization, and Calibration of a Human Physiologically Based Pharmacokinetic Model for the Plasticizer, Hexamoll® Diisononyl-Cyclohexane-1, 2-Dicarboxylate Using In Silico, In Vitro, and Human Biomonitoring Data

A physiologically based pharmacokinetic model for Hexamoll® diisononyl-cyclohexane-1, 2-dicarboxylate was developed to interpret the biokinetics in humans after single oral doses. The model was parameterized with in vitro and in silico derived parameters and uncertainty and sensitivity analysis was used during the model development process to assess structure, biological plausibility and behavior prior to simulation and analysis of human biological monitoring data. The model provided good simulations of the urinary excretion (Curine) of two metabolites; cyclohexane-1,2-dicarboxylic acid mono hydroxyisononyl ester (OH-MINCH) and cyclohexane-1, 2-dicarboxylic acid mono carboxyisononyl ester (cx-MINCH) from the biotransformation of mono-isononyl-cyclohexane-1, 2-dicarboxylate (MINCH), the monoester metabolite of di-isononyl-cyclohexane-1,2-dicarboxylate. However, good simulations could be obtained, with and without, a lymphatic compartment. Selection of an appropriate model structure was informed by sensitivity analysis which could identify and quantify the contribution to variability in Curine by parameters, such as, the fraction of oral dose that directly entered the lymphatic compartment and therefore by-passed the liver and the fraction of MINCH bio-transformed to cx-MINCH and OH-MINCH. By constraining these parameters within biologically plausible limits the presence of a lymphatic compartment was deemed an important component of model structure. Furthermore, the use of sensitivity analysis is important in the evaluation of uncertainty around in silico derived parameters. By quantifying their impact on model output sufficient confidence in the use of a model should be afforded. This type of approach could expand the use of physiologically based pharmacokinetic models since parameterization with in silico techniques allows for rapid model development. This in turn could assist in reducing the use of animals in toxicological evaluations by enhancing the utility of “read across” techniques.

[1]  H. Clewell,et al.  An evaluation of the USEPA Proposed Approaches for applying a biologically based dose‐response model in a risk assessment for perchlorate in drinking water , 2019, Regulatory toxicology and pharmacology : RTP.

[2]  Patrick Poulin,et al.  Advancing prediction of tissue distribution and volume of distribution of highly lipophilic compounds from a simplified tissue-composition-based model as a mechanistic animal alternative method. , 2012, Journal of pharmaceutical sciences.

[3]  J. Valentin.  Basic anatomical and physiological data for use in radiological protection: reference values , 2002, Annals of the ICRP.

[4]  Peter J Boogaard,et al.  Human biomonitoring as a pragmatic tool to support health risk management of chemicals--examples under the EU REACH programme. , 2011, Regulatory toxicology and pharmacology : RTP.

[5]  George Loizou,et al.  MEGen: A Physiologically Based Pharmacokinetic Model Generator , 2011, Front. Pharmacol..

[6]  Hadley Wickham,et al.  Reshaping Data with the reshape Package , 2007 .

[7]  L Earl Gray,et al.  Cumulative effects of dibutyl phthalate and diethylhexyl phthalate on male rat reproductive tract development: altered fetal steroid hormones and genes. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[8]  N. Di Lascio,et al.  Tissue distribution of drug-metabolizing enzymes in humans. , 1988, Xenobiotica; the fate of foreign compounds in biological systems.

[9]  Mario Lobell,et al.  In silico prediction of aqueous solubility, human plasma protein binding and volume of distribution of compounds from calculated pKa and AlogP98 values , 2004, Molecular Diversity.

[10]  Amin Rostami-Hodjegan,et al.  Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.

[11]  Holger M Koch,et al.  Human body burdens of chemicals used in plastic manufacture , 2009, Philosophical Transactions of the Royal Society B: Biological Sciences.

[12]  A. Gelman,et al.  Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior Distributions , 1996 .

[13]  W. Kessler,et al.  Kinetics of di(2-ethylhexyl) phthalate (DEHP) and mono(2-ethylhexyl) phthalate in blood and of DEHP metabolites in urine of male volunteers after single ingestion of ring-deuterated DEHP. , 2012, Toxicology and applied pharmacology.

[14]  Marie Laure Delignette-Muller,et al.  Evaluating variability and uncertainty separately in microbial quantitative risk assessment using two R packages. , 2010, International journal of food microbiology.

[15]  D J Rance,et al.  The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.

[16]  N. Davies,et al.  Lymphatic Drug Absorption via the Enterocytes: Pharmacokinetic Simulation, Modeling, and Considerations for Optimal Drug Development. , 2018, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[17]  Corie A Ellison,et al.  Structural and functional pharmacokinetic analogs for physiologically based pharmacokinetic (PBPK) model evaluation , 2018, Regulatory toxicology and pharmacology : RTP.

[18]  A. Edginton,et al.  Population physiologically-based pharmacokinetic model incorporating lymphatic uptake for a subcutaneously administered pegylated peptide , 2016, In Silico Pharmacology.

[19]  Hiroshi Yamazaki,et al.  Combining Chimeric Mice with Humanized Liver, Mass Spectrometry, and Physiologically-Based Pharmacokinetic Modeling in Toxicology. , 2016, Chemical research in toxicology.

[20]  Jerry L. Campbell,et al.  In vitro intestinal and hepatic metabolism of Di(2-ethylhexyl) phthalate (DEHP) in human and rat. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.

[21]  A. Petrauskas,et al.  ACD/Log P method description , 2000 .

[22]  Hugh A Barton,et al.  Evaluation of physiologically based pharmacokinetic models for use in risk assessment , 2007, Journal of applied toxicology : JAT.

[23]  Han van de Waterbeemd,et al.  Lipophilicity in PK design: methyl, ethyl, futile , 2001, J. Comput. Aided Mol. Des..

[24]  S. Gangolli,et al.  Aspects of the testicular toxicity of phthalate esters. , 1986, Environmental health perspectives.

[25]  M. Dalgaard,et al.  Diisobutyl phthalate has comparable anti-androgenic effects to di-n-butyl phthalate in fetal rat testis. , 2006, Toxicology letters.

[26]  Walter Schmitt,et al.  General approach for the calculation of tissue to plasma partition coefficients. , 2008, Toxicology in vitro : an international journal published in association with BIBRA.

[27]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[28]  Andrew Worth,et al.  Investigating the state of physiologically based kinetic modelling practices and challenges associated with gaining regulatory acceptance of model applications , 2017, Regulatory toxicology and pharmacology : RTP.

[29]  T. Brüning,et al.  Metabolism of the plasticizer and phthalate substitute diisononyl-cyclohexane-1,2-dicarboxylate (DINCH®) in humans after single oral doses , 2012, Archives of Toxicology.

[30]  Claude Viau,et al.  Biomonitoring for occupational health risk assessment (BOHRA). , 2010, Toxicology letters.

[31]  M. van der Put,et al.  Solving differential equations , 2008, 0810.4039.

[32]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[33]  George Loizou,et al.  Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. , 2008, Regulatory toxicology and pharmacology : RTP.

[34]  B. Burchell,et al.  In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. , 2002, The Journal of pharmacology and experimental therapeutics.

[35]  M. Andersen,et al.  Risk Assessment Extrapolations and Physiological Modeling , 1985, Toxicology and industrial health.

[36]  J. Furr,et al.  Perinatal exposure to the phthalates DEHP, BBP, and DINP, but not DEP, DMP, or DOTP, alters sexual differentiation of the male rat. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[37]  Kevin McNally,et al.  The application of global sensitivity analysis in the development of a physiologically based pharmacokinetic model for m-xylene and ethanol co-exposure in humans , 2015, Front. Pharmacol..

[38]  T. Brüning,et al.  Identifying sources of phthalate exposure with human biomonitoring: results of a 48h fasting study with urine collection and personal activity patterns. , 2013, International journal of hygiene and environmental health.

[39]  John C Lipscomb,et al.  Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. , 2007, Current drug metabolism.

[40]  George Loizou,et al.  Reconstruction of Exposure to m-Xylene from Human Biomonitoring Data Using PBPK Modelling, Bayesian Inference, and Markov Chain Monte Carlo Simulation , 2012, Journal of toxicology.

[41]  M. Jamei,et al.  Misuse of the Well-Stirred Model of Hepatic Drug Clearance , 2007, Drug Metabolism and Disposition.

[42]  G. Loizou,et al.  A human PBPK model for ethanol describing inhibition of gastric motility , 2004, Journal of Molecular Histology.

[43]  R. Mannhold,et al.  Calculation of molecular lipophilicity: state of the art and comparison of methods on more than 96000 compounds , 2009, Journal of pharmaceutical sciences.

[44]  Hannah M Jones,et al.  SUBSTRATE DEPLETION APPROACH FOR DETERMINING IN VITRO METABOLIC CLEARANCE: TIME DEPENDENCIES IN HEPATOCYTE AND MICROSOMAL INCUBATIONS , 2004, Drug Metabolism and Disposition.

[45]  George Loizou,et al.  Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[46]  Karline Soetaert,et al.  Solving Differential Equations in R: Package deSolve , 2010 .

[47]  E. Fabian,et al.  In vitro-to-in vivo extrapolation (IVIVE) by PBTK modeling for animal-free risk assessment approaches of potential endocrine-disrupting compounds , 2018, Archives of Toxicology.

[48]  R. Obach,et al.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[49]  J. Dearden.  In silico prediction of aqueous solubility , 2006, Expert opinion on drug discovery.

[50]  Robert G. Pearce,et al.  httk: R Package for High-Throughput Toxicokinetics. , 2017, Journal of statistical software.

[51]  Kevin McNally,et al.  A probabilistic model of human variability in physiology for future application to dose reconstruction and QIVIVE , 2015, Front. Pharmacol..

[52]  Kevin McNally,et al.  A Workflow for Global Sensitivity Analysis of PBPK Models , 2011, Front. Pharmacol..

[53]  Kevin McNally,et al.  PopGen: A virtual human population generator. , 2014, Toxicology.

[54]  Andrew Worth,et al.  Challenges in working towards an internal threshold of toxicological concern (iTTC) for use in the safety assessment of cosmetics: Discussions from the Cosmetics Europe iTTC Working Group workshop , 2019, Regulatory toxicology and pharmacology : RTP.

[55]  M. A. Wouters,et al.  Potential role of glutathione in evolution of thiol-based redox signaling sites in proteins , 2015, Frontiers in Pharmacology.

[56]  J. Furr,et al.  A short-term in vivo screen using fetal testosterone production, a key event in the phthalate adverse outcome pathway, to predict disruption of sexual differentiation. , 2014, Toxicological sciences : an official journal of the Society of Toxicology.

[57]  R. H. Mckee,et al.  Esters of Aromatic Mono‐, Di‐, and Tricarboxylic Acids, Aromatic Diacids and Di‐, Tri‐, Or Polyalcohols , 2001 .

[58]  G. Tucker,et al.  Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability , 2006, Xenobiotica; the fate of foreign compounds in biological systems.